New York, December 20, 2023 - Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). https://prismmarketview.com/companies/lipella-pharmaceuticals-inc/ Today, the company announced it has successfully completed a Type C meeting with...
![PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success](https://prismmediawire.com/wp-content/uploads/2023/12/Lipo-Newsroom-1080x675.png)